TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01006291

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec
Description: Injected s.c. (under the skin) once daily (alternative regimen). Dose was individually adjusted.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec
Description: Injected s.c. (under the skin) once daily. Dose was individually adjusted.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin glargine
Description: Insulin glargine injected s.c. (under the skin) once daily. Dose was individually adjusted.
Study: NCT02105662

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Grazoprevir 100 mg/Elbasvir 50 mg fixed-dose combination tablets
Description: MK-5172A FDC tablet: MK-5172 (100 mg)/MK-8742 (50 mg)
Study: NCT04651504

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Colorectal Cancer Toolkit
Description: The intervention toolkit will include patient education materials and supportive materials for providers. Tracking systems and supports will be jointly developed with participating clinic and providers, in order to maximize their existing systems and develop processes that meet their needs and preferences, and training will be offered to help providers/teams efficiently use the tracking system and clinic resources. The study team will provide technical assistance and support through email, phone and zoom to support the clinic in their implementation process.
Study: NCT05426603

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pulmonary vein isolation
Description: The 3D geometry of the LA will be created using CARTO 3 system (version 6) with UDM Module and VISITAG Optimum Device Performance (ODP) module. Continuous circumferential lesions will then be created encircling the right and left PV ostia using a 7.5F, 3.5-mm Thermocool SMARTTOUCH ablation catheter (Biosense Webster, Inc., Diamond Bar, CA, USA).Pentaray catheter will be used and facilitate the high density mapping of atrial substrate (PentarayTM, Biosense Webster Inc., Diamond Bar, CA, USA). The radiofrequency energy will be applied with contact force range 5-25 g continuously with a target Ablation Index target 380-400 on the posterior wall and 550 - 600 on the anterior wall and maximum power of 25-35W in a power control mode

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Pulmonary vein isolation
Description: The 3D geometry of the LA will be created using CARTO 3 system (version 6) with UDM Module and VISITAG Optimum Device Performance (ODP) module. Continuous circumferential lesions will then be created encircling the right and left PV ostia using a 7.5F, 3.5-mm Thermocool SMARTTOUCH ablation catheter (Biosense Webster, Inc., Diamond Bar, CA, USA).Pentaray catheter will be used and facilitate the high density mapping of atrial substrate (PentarayTM, Biosense Webster Inc., Diamond Bar, CA, USA). The radiofrequency energy will be applied with contact force range 5-25 g continuously with a target Ablation Index target 380-400 on the posterior wall and 550 - 600 on the anterior wall and maximum power of 25-35W in a power control mode

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Substrate ablation(PRISM based)
Description: Substrate modification will be guided by waveform periodicity analysis. The User Defined Map of waveform periodicity analysis will be also created by CARTO 3 system (version 6) with and VISITAG ODP module. Pentaray catheter will be used and facilitate the high density mapping of atrial substrate (PentarayTM, Biosense Webster Inc., Diamond Bar, CA, USA). Substrate modification based on waveform periodicity analysis will be performed by using a 7.5F, 3.5-mm Thermocool SMARTTOUCH ablation catheter (Biosense Webster, Inc., Diamond Bar, CA, USA). The radiofrequency energy will be applied with contact force range 5-25 g continuously with a target Ablation Index target 380-400 on the posterior wall and 550 - 600 on the anterior wall and maximum power of 25-35W in a power control mode.
Study: NCT03063034

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PD21864AA
Description: A king size menthol cigarette.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PD21864AA
Description: A king size menthol cigarette.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PD21864AB
Description: A king size menthol cigarette.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PD21864AB
Description: A king size menthol cigarette.
Study: NCT04463459

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin C, Vitamin E
Description: Vitamin C (500mg) twice daily and Vitamin E (400mg) once daily
Study: NCT03079102

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitric Oxide
Description: An endogenous gaseous signaling molecule which stimulates soluble guanylate cyclase and may act via S-nitrosation, nitrite/nitrate or nitrated fatty acid formation.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nitrogen
Description: Nitrogen is the carrier gas (vehicle) for iNO. Subjects receiving placebo will receive equivalent doses of nitrogen.
Study: NCT03574519

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Non-contingent incentives
Description: Incentives are provided for participation

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Non-contingent incentives
Description: Incentives are provided for participation

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contingent incentives
Description: Incentives are provided for attaining daily goals

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contingent incentives
Description: Incentives are provided for attaining daily goals

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weekly feedback
Description: Text message feedback is delivered weekly summarizing the past week's progress

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weekly feedback
Description: Text message feedback is delivered weekly summarizing the past week's progress

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Daily feedback
Description: Text message feedback is delivered daily summarizing the current day's progress

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Daily feedback
Description: Text message feedback is delivered daily summarizing the current day's progress
Study: NCT02479308

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: Single administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALKS 5461
Description: Daily administration for a total of 12 dosing days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be matched to Moxifloxacin or ALKS 5461
Study: NCT04606329

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LuminoMark inj.(Conc. for fluorescence)
Description: Injection LuminoMark inj. (Conc. for fluorescence) 0.2mL once in this study.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Charcotrace Inj.
Description: Injection Charcotrace Inj. about 0.3\~1mL once in this study.
Study: NCT04177576

Intervention type: BIOLOGICAL
Intervention: 2 additional tubes of blood
Description: 2 additional tubes of blood will be collected to prepare plasma aliquots used tomeasure markers of neutrophil activation
Study: NCT02800629

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Modified Citrus Pectin
Description: MCP versus placebo

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01074593

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Interferon beta-1a
Description: 12.000UI - single dose

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Interferon beta-1a
Description: 12.000UI - Single dose
Study: NCT03788772

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multiple blood sampling
Description: ICU septic and non-septic patients will be subjected to repeated blood samples at the following time-points: ICU admission, day 4/5, ICU and hospital discharge, 3 months. Patients exhibiting ICU-acquired infection will also be sampled at the time of diagnosis (up to 6 additional blood samples of 20 mL within 3 months = 120mL)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Simple blood sampling
Description: Healthy controls (blood donors and patients undergoing elective cataract surgery) will be subjected to one single blood sample of 20 mL.
Study: NCT00295880

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: umbilical cord blood transplantation
Description: The graft will be given by slow injection into each posterior iliac crest.
Study: NCT03773796

Intervention type: DRUG
Group type: OTHER
Intervention: Nabilone 0.25 mg
Description: capsules, 0.25 mg up to 2 mg of nabilone taken orally on a daily basis
Study: NCT03192371

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rabipur
Description: Rabies vaccine administered as an intramuscular injection according to Zagreb or Essen regimen to subjects aged ≥6 to ≤17 years.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rabipur
Description: Rabies vaccine administered as an intramuscular injection according to Zagreb or Essen regimen to subjects aged ≥6 to ≤17 years.
Study: NCT02175199

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lotrafilcon B contact lenses with color printing

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Phemfilcon A contact lenses with color printing
Study: NCT01111578

Intervention type: DEVICE
Intervention: Enteral feeding tube
Description: The esophageal and gastric pressure, measured with this new device, will be recorded and compared with those ones measured with a standard esophageal catheter
Study: NCT02260180

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: A-101
Description: Topical Solution

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: A-101
Description: Topical Solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: A-101
Description: Topical Solution
Study: NCT04319692

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fermented Prunus Mume Vinegar group
Description: This group takes Fermented Prunus Mume Vinegar for 8 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo group
Description: This group takes placebo for 8 weeks.
Study: NCT02664948

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Early geriatric follow-up after discharge
Description: Multidisciplinary assessement and intervention by physician, nurse and physiotherapist
Study: NCT01043289

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Light therapy
Description: During the 5-week treatment period, subjects sit in front of a light box for 60 minutes daily after awakening, at a specified distance that provides the required light intensity.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Light therapy
Description: During the 5-week treatment period, subjects sit in front of a light box for 60 minutes daily after awakening, at a specified distance that provides the required light intensity.
Study: NCT01048632

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxandrolone
Description: 2.5 mg oxandrolone tablets.Based upon the patient's body weight, the coordinator, PI or sub-PI will determine the appropriate dose of oxandrolone (0.1 mg/kg/dose twice daily via the buccal mucosa.)
Study: NCT01047605

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neurapas balance
Description: 6 tablets single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pascoflair 425 mg
Description: 3 tablets , single dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: P-Tabletten weiß
Description: 3 tablets, single dose
Study: NCT01322841

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CHICA Diagnosis Module
Description: The CHICA module helped to screen and diagnose patients with tuberculosis or iron deficiency anemia

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: CHICA Placebo
Description: This was CHICA without the screening module
Study: NCT04065737

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: Sintilimab is a type of immunotherapy. Immunotherapy works by encouraging the body's own immune system to attack cancer cells.~other name: IBI308
Study: NCT02513927

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metoprolol
Description: Metoprolol was given orally in a dose of 95 mg/day to treat patients in the metoprolol group for 12 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metoprolol
Description: Metoprolol was given orally in a dose of 95 mg/day to treat patients in the metoprolol group for 12 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nifedipine
Description: Nifedipine was given orally in a dose of 30 mg/day to treat patients in the amlodipine group for 12 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nifedipine
Description: Nifedipine was given orally in a dose of 30 mg/day to treat patients in the amlodipine group for 12 weeks.
Study: NCT02273596

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALXN1840
Description: Individualized oral doses of ALXN1840.
Study: NCT02267876

Intervention type: DEVICE
Intervention: BD HPV Assay on Viper LT
Description: The BD HPV specimen will be tested with the BD HPV Assay on the Viper LT instrument.

Intervention type: PROCEDURE
Intervention: Colposcopy
Description: The colposcopy will be performed on subjects that have abnormal cytology. At the third year visit all subjects will have an exit colposcopy.
Study: NCT01401660

Intervention type: OTHER
Intervention: Physical Therapy
Description: The physician will complete a physical exam as well as analyze a completed CERSR® scan study to determine the root cause of the low back pain. The physician will then prescribe a targeted physical therapy regime to address the cause of the low back pain.
Study: NCT01732601

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive Outpatient CBT
Description: Sessions will be delivered 1-2 times a week for the first 4-6 weeks, based on need, and then weekly until 6 months. Therapy can continue up until one year.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: Treatment at step-down facilities
Study: NCT01864382

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Core stability
Description: Core stability 5 days a week during 5 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Physiotherapy Exercises
Description: Standard Physiotherapy Exercises is a conventional treatment program 5 days a week during 5 weeks

Intervention type: OTHER
Group type: OTHER
Intervention: Standard Physiotherapy Exercises
Description: Standard Physiotherapy Exercises is a conventional treatment program 5 days a week during 5 weeks
Study: NCT03565952

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cranial massage
Description: Manual cranial therapy consisting of massage and cranial relaxing techniques, lasting 30 minutes each session approximately, for 3 weeks and one month follow-up. Manual therapy consists of a prone and supine cranial massage.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: The control group does not receive treatment
Study: NCT04267913

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Given IV

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Ramucirumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sapanisertib
Description: Given PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sapanisertib
Description: Given PO
Study: NCT02185859

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: The lidocaine group (Group L)- 1% lidocaine 40 mL is prepared in a 50 mL syringe; A bolus dose of the studied drugs are administered for 15 minutes immediately after a subject is brought into the operating room, and the vital signs are checked (from the beginning of anesthesia induction). Subsequently, an intravenous injection of the maintenance dose is continuously performed and later stopped just before transferring the subject to a recovery room. (Group L subjects are administered lidocaine 2 mg/kg for 15 minutes immediately after the anesthesia induction, and then lidocaine 2 mg/kg/h is continuously injected. The dose of lidocaine and magnesium in this study has been shown in previous studies to be safe and to have an analgesic effect.)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium Sulfate
Description: the magnesium group (Group M)- MgSO4 4g 40 mL is prepared in a 50 mL syringe.) A bolus dose of the studied drugs are administered for 15 minutes immediately after a subject is brought into the operating room, and the vital signs are checked (from the beginning of anesthesia induction). Subsequently, an intravenous injection of the maintenance dose is continuously performed and later stopped just before transferring the subject to a recovery room. The dose of magnesium in this study has been shown in previous studies to be safe and to have an analgesic effect.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saline
Description: the control group (Group C) - 0.9% normal saline 40 mL is prepared in a 50 cc syringe. A bolus dose of the studied drugs are administered for 15 minutes immediately after a subject is brought into the operating room, and the vital signs are checked (from the beginning of anesthesia induction). Subsequently, an intravenous injection of the maintenance dose is continuously performed and later stopped just before transferring the subject to a recovery room.Group C subjects are administered the same dose of normal saline.
Study: NCT00543959

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK0533
Description: Initially a 12-wk study of MK0533 30mg, switching at week 12 to a study of daily administration MK0533 5mg, MK0533 15mg, MK0533 30mg. Study period is a total of 24-wks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK0533
Description: Initially a 12-wk study of MK0533 30mg, switching at week 12 to a study of daily administration MK0533 5mg, MK0533 15mg, MK0533 30mg. Study period is a total of 24-wks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK0533
Description: Initially a 12-wk study of MK0533 30mg, switching at week 12 to a study of daily administration MK0533 5mg, MK0533 15mg, MK0533 30mg. Study period is a total of 24-wks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK0533
Description: Initially a 12-wk study of MK0533 30mg, switching at week 12 to a study of daily administration MK0533 5mg, MK0533 15mg, MK0533 30mg. Study period is a total of 24-wks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Placebo (unspecified)
Description: MK0533 Placebo; MK0533 5mg; MK0533 15mg; MK0533 30mg. Study period is a total of 24 wks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Placebo (unspecified)
Description: MK0533 Placebo; MK0533 5mg; MK0533 15mg; MK0533 30mg. Study period is a total of 24 wks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: pioglitazone
Description: pioglitazone 45mg. Study period is a total of 24 wks.
Study: NCT02905851

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Feedback group
Description: Monitoring ability to use teledermatology to modify antibiotic burden

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Non Feedback group
Description: To use as control to see if antibiotic burden has been reduced in the active feedback group
Study: NCT01795170

Intervention type: DIETARY_SUPPLEMENT
Intervention: Lysine Restricted Diet
Description: Daily lysine intake will be managed to maintain a plasma lysine level of 50-80 µmol/L (normal range: 52-196 µmol/L). Diet prescriptions will be based on international guidelines for glutaricaciduria type I, another inborn error of lysine catabolism. In order to meet the recommended daily protein intake (DRI) \[23,24\], the diet may include commercially available lysine-free amino acid formulas approved for use in conditions affecting lysine metabolism, as well as commercially available low-protein products based on the participant's taste.

Intervention type: DRUG
Intervention: Pyridoxine
Description: All participants will be on 15-30 mg/kg/day of pyridoxine therapy up to a maximum of 500mg/day divided in 2-3 doses enterally

Intervention type: DRUG
Intervention: Pyridoxine
Description: All participants will be on 15-30 mg/kg/day of pyridoxine therapy up to a maximum of 500mg/day divided in 2-3 doses enterally
Study: NCT02741518

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fecal Microbiota Transplantation
Description: This is pre-screened fecal material that has been encapsulated

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: These are capsules that have no fecal material in them.
Study: NCT02384798

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: noninvasive ventilatory support
Description: noninvasive ventilatory support with 5-minute ramp and positive end expiratory pressure (PEEP) of 5 cm H2O for 30 minutes, then there will be the interval aerobic training on a treadmill added to resistance exercises

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: interval training
Description: interval training

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: interval training
Description: interval training
Study: NCT04044170

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Poziotinib
Description: The poziotinib drug substance is a hydrochloride salt of poziotinib and is formulated as a tablet for oral administration.
Study: NCT01278472

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Single Port Cholecystectomy
Description: Using transumbilical single port device: SILS Port
Study: NCT01411085

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperidone + Desipramine
Study: NCT01278472

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 4 Port Cholecystectomy
Description: using 4 separate skin incisions and 2 5mm and 2 12 mm conventional ports
Study: NCT00632788

Intervention type: OTHER
Intervention: acute myocardial infarction checklist
Description: For every patient fulfilling the criteria of enrollment, an acute myocardial infarction checklist was incorporated into the patient's medical records at emergency department immediately after a diagnosis of acute ST-elevation myocardial infarction was made. All the time sequences concerning different managements at different locations were recorded by nurses and/or physicians as instructions on the checklist.